Applera Corporation of Norwalk, Conn., has received US Patent No. 6,900,040, "Isolated human dehydrogenaseproteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof." The patented described a DNA microarray that can be used to develop gene expression profiles based on the amino acid sequences of human dehydrogenase polypeptides and proteins. These peptides and proteins are related to the retinol dehydrogenase subfamily, as well as allelic variants and other mammalian orthologs. The peptide sequences as well as the nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate dehydrogenase activity in cells and tissues that express the dehydrogenase.
Beth Israel Deaconess Medical Center of Boston and Cornell Research Foundation of Ithaca, NY, have received US Patent No. 6,900,015, "Measurement of protective genes in allograft rejection." The patented invention describes methods and compositions for monitoring the status of and for treating a transplanted organ in a host. In certain aspects, the present invention relates to evaluating transplant rejection in a host by determining the magnitude of gene expression in a post-transplant biological sample obtained from the host and comparing the relative expression of the marker genes to a baseline level of expression of the immune activation marker, Up-regulation of gene expression of two or more selected genes in the sample indicates rejection, and down-regulation of gene expression is indicative of a non-rejection state. As a result of the work described in the patent, methods are available to quantify marker gene expression in biopsy tissue, urine, peripheral blood mononuclear cells and other body fluids, and to correlate the magnitude of expression of these genes with rejection of allografts. The evaluation of the expression of marker genes in a post-transplant sample, along with the evaluation of expression of an infectious agent gene, also detects allograft rejection.
The Regents of the University of Michigan of Ann Arbor, MI, have received US Patent No. 6,902,933, "Surface transfection and expression procedure." The patent describes a method of transfecting cells comprising applying cells directly onto nucleic acids that are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the patent states, the nucleic acids are immobilized in an array, which can be an ordered or random array. The method further includes expression of the nucleic acids in the transfected cells and further comprises detecting the expression of the nucleic acids in the transfected cells.
Proligo of Boulder, Colo., has received US Patent No. 6,902,900, "Nucleic acid probes and methods to detect and/or quantify nucleic acid analytes." The patented invention describes methods and strategies to detect and/or quantify nucleic acid analytes. The methods use nucleic acid probes with covalently conjugated dyes, which are attached either at adjacent nucleotides or at the same nucleotide of the probe and novel linker molecules to attach the dyes to the probes. The nucleic acid probes generate a fluorescent signal upon hybridization to complementary nucleic acids based on the interaction of one of the attached dyes, which is either an intercalator or a DNA groove binder, with the formed double stranded DNA. The patent states that the methods can be applied to a variety of applications including homogeneous assays, real-time PCR monitoring, transcription assays, expression analysis on nucleic acid microarrays and other microarray applications such as SNP genotyping. The described methods further include pH-sensitive nucleic acid probes that provide switch-able fluorescence signals that are triggered by a change in the pH of the medium.